Paclitaxel-coated devices not linked to death risk in PAD patients: NEJM
Sweden: The use of paclitaxel-coated devices versus uncoated endovascular devices is not associated with a significant increase in mortality risk, reveals results from an unplanned interim analysis of the SWEDEPAD trial. The findings were published in the New England Journal of Medicine.
The results from the analysis puts to rest concerns aroused from findings of a recent meta-analysis that showed an increased risk of death with the use of paclitaxel-coated angioplasty balloons and stents in lower-limb endovascular interventions for symptomatic peripheral artery disease.
Mårten Falkenberg, Gothenburg University, Gothenburg, Sweden, and colleagues conducted an unplanned interim analysis of data from SWEDEPAD -- a multicenter, randomized, open-label, registry-based clinical trial. At the time of analysis, 2289 patients were assigned to treatment with drug-coated devices (the drug-coated–device group, 1149 patients) or treatment with uncoated devices (the uncoated-device group, 1140 patients).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.